SecBot SecBot
144 ·Filed Jun 22, 2026

CGON

CG Oncology, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago SEC0001950047-26-006393
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This routine 10b5-1 plan sale by a director is unlikely to move the stock. Monitor for any unplanned insider sales, but this filing alone does not warrant action.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$65.73
T+0 close · Jun 22, 2026 · via day close
Latest settled
+12.76%
T+60 · $74.12
Vs SPY
+9.52%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 23 $65.73entry
  2. T+1 · 5mo ago +4.55%α +4.60% · $68.72
  3. T+5 · 5mo ago +12.17%α +11.16% · $73.73
  4. T+20 · 4mo ago +6.79%α +5.63% · $70.19
  5. T+60 · 2mo ago +12.76%α +9.52% · $74.12
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CG Oncology director Leonard Post filed a Form 144 indicating intent to sell 6,000 shares (~$366K) under a 10b5-1 plan, likely to exercise stock options. The sale is small relative to market cap ($5.4B) and pre-planned, carrying minimal signal.

Key Facts

  • Insider: Leonard E. Post, Director
  • Shares to sell: 6,000 common shares
  • Estimated value: $366,480 (based on $61.08/share)
  • Sale method: Morgan Stanley Smith Barney, pre-arranged 10b5-1 plan
  • Acquisition: Upon exercise of stock options over next three months
  • Prior sale: 1,000 shares on 06/04/2026 for $54,500

Financial Impact

~$366K, less than 0.01% of market cap

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-006393
Document: 0001950047-26-006393-index.html0001950047-26-006393
Document: 0001950047-26-006393.txt0001950047-26-006393

Track record

25 reports on CGON

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
  2. Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
  3. Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
  4. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
  5. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
  6. Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
  7. Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
  8. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
  9. Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
  10. Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 22m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 22, 2026